Behind the video
Hims & Hers Stock: Why This Is a 10x Stock
The thesis, the calls, and the words behind them. Play a quote to hear it in the original video.
Overall SentimentBullishStrength: 95%
Overall Thesis
Hims & Hers can become a dominant healthcare platform by aggregating consumer demand, attracting suppliers and improving personalization through labs and AI. The host considers its valuation exceptionally attractive and endorses it as his largest holding, with potential for extraordinary investment returns if it becomes a global healthcare platform.
Narratives
HIMSHims & Hers Health
Strongly BullishThe host sees Hims & Hers as a healthcare demand aggregator whose customer relationships, data and expanding specialties can reinforce one another and attract pharmaceutical supply. He regards the current sales multiple as a bargain, endorses maintaining his largest portfolio holding and sees potential for 100-fold returns if the company wins globally.
Key Arguments
- Consumer choice and control of the customer interface can create platform advantages comparable to Netflix and Uber.
- Labs, AI and personalized health data can improve treatments and strengthen subscriber retention and acquisition.
- Expanding specialties create cross-selling opportunities and a subscriber-data-personalization flywheel.
- Partnerships with Novo Nordisk and access to Eli Lilly products expand supply and could support subscriber growth and revenue per subscriber.
- The host cites more than 50% of observed telehealth sales in 2025 as evidence of competitive strength.
- International acquisitions expand the addressable market and subscriber base.
- Avoiding insurance supports transparent pricing and a different incentive structure from traditional healthcare.
- The host estimates second-half revenue growth could approach 50% including Eucalyptus, making roughly 3.5 times sales attractive.
- He prioritizes platform growth over near-term profitability and sees potential for stronger monetization after achieving scale.
Risks acknowledged
- Recent growth has slowed and margins face pressure.
- GLP-1 availability changes and Novo Nordisk litigation previously disrupted the business.
- Ro's advertising campaign temporarily reduced Hims & Hers' market share.
- International expansion risks diverting management attention from the US.
- Global platform dominance remains conditional.
Hedges & Caveats
- Recent revenue growth has slowed and margins are under pressure, although the host expects these pressures to be temporary.
- Compounded GLP-1 restrictions and litigation previously created substantial headwinds.
- Ro temporarily gained market share through a major advertising campaign.
- International expansion could distract management from the US business.
- The 100-fold upside scenario depends on winning globally; it is presented as potential rather than a guaranteed outcome.
Analyzed with codex-cli-scheduled | Extraction manual_v1 | Cost: —